WELCOME AND INTRODUCTION
Siew Eng Choon, MBBS, FRCP, Malaysia
A Patient-Inclusive Approach in the Treatment of Psoriasis: A Principal Without Borders
Claudia de la Cruz, MD, Chile
An International Perspective on Value-Based Healthcare
Jo Lambert, MD, PhD, Belgium
Genetic Differences Across the Globe
Johann Gudjonsson, MD, PhD, United States
Pitfalls in Diagnosis and Phenotypic Differences Related to Skin of Color
Mohammad Huq, MBBS. DDSc, MSc-Dermatology, MPH, Bangladesh
BREAK
Therapeutic Challenges Related to Skin of Color
Mahira El Sayed, MSc, MD, Egypt
Comorbidities of Psoriasis Across the World
Kathleen Gallant, MPA, United States
Availability of Therapies Across the World: Data from the GPA
Chris Griffiths, OBE, MD, FMedSci, United Kingdom
Every Patient in the World has the Right to Optimal Treatment
Hoseah Waweru, MD, Kenya
CLOSING COMMENTS AND ADJOURN
Claudia de la Cruz, MD, Chile
IPC Councilor Helen Young provides commentary on a study identifying skin-derived myeloid precursors and CD200+ fibroblasts as key drivers of psoriatic disease spread from the skin to joints, highlighting the CD200–CD200R1 axis as a promising therapeutic target.
IPC Fellow Dr. Yemsrach Abawaji shares her firsthand perspective on the barriers to psoriasis diagnosis and treatment in Ethiopia and opportunities to improve care.
Did you miss the IPC symposium at the 83rd Society for Investigative Dermatology (SID) Annual Meeting? Select session videos are now available. The Arc of Disease Control in Psoriasis: Early Interception – Deep Pathway Blockade – Treatment Failure covered early intervention strategies, treatment selection, immune pathway targeting, PsA prevention, clinical escape, and real-world cases that inform long-term psoriasis care.
Depression affects approximately 20% of patients with psoriasis, five times the rate seen in the general population. IPC Jr. Councilor Mio Nakamura, MD, MS, FAAD, walks through the bidirectional relationship between psoriasis and depression, the shared inflammatory pathways driving both conditions, and practical guidance on screening and incorporating multidisciplinary mental health support into psoriasis management.
